Phase 3 trial assesses clazakizumab in kidney transplant recipients with caAMR

Study: "Clazakizumab in Chronic Active Antibody-Mediated Kidney Transplant Rejection: Results of the IMAGINE Phase 3 Study"

Source:

American Society of Nephrology